#### Neos Therapeutics, Inc. Form 3 July 22, 2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION OMB APPROVAL FORM 3 Washington, D.C. 20549 OMB Number:

## **INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

## (Print or Type Responses)

1. Name and A Person <u>*</u> Tengler M		porting	2. Date of Event Requiring Statement (Month/Day/Year)	3. Issuer Name <b>and</b> Ticker or Trading Symbol Neos Therapeutics, Inc. [NEOS]				
(Last)	(First)	(Middle)	07/22/2015	4. Relationship of Reporting Person(s) to Issuer			5. If Amendment, Date Original Filed(Month/Day/Year)	
C/O NEOS	THERAPE	UTICS.					Thed(wond) Day Teal)	
INC., 2940			(Check all applicable)					
(Street) GRAND PRAIRIE, TX 75050				Director10% Owner XOfficerOther (give title below) (specify below) Chief Technology Officer			<ul> <li>6. Individual or Joint/Group</li> <li>Filing(Check Applicable Line)</li> <li>_X_ Form filed by One Reporting</li> <li>Person</li> <li> Form filed by More than One</li> <li>Reporting Person</li> </ul>	
(City)	(State)	(Zip)	Table I - N	Non-Derivat	ive Securiti	es Bei	neficially Owned	
1.Title of Secu (Instr. 4)	rity		2. Amount o Beneficially (Instr. 4)		3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nat Owne (Instr.	1	
Common St	ock		109,560		D	Â		
Reminder: Rep owned directly	-	ate line for ea	ch class of securities benefic	<sup>ially</sup> S	EC 1473 (7-02	)		
	inform	nation conta	pond to the collection of ained in this form are not nd unless the form displ	t				

#### Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

currently valid OMB control number.

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) Title	4. Conversion or Exercise Price of Derivative	5. Ownership Form of Derivative Security:	6. Nature of Indirect Beneficial Ownership (Instr. 5)
		THE	Security	Direct (D)	

3235-0104

January 31,

2005

0.5

Expires:

response...

Estimated average burden hours per

## Edgar Filing: Neos Therapeutics, Inc. - Form 3

	Date Exercisable	Expiration Date		Amount or Number of Shares		or Indirect (I) (Instr. 5)	
Series C Preferred Stock	(1)	(1)	Common Stock	2,500	\$ <u>(1)</u>	D	Â
Stock Option (Right to Buy)	(2)	05/03/2023	Common Stock	4,445	\$ 2.55	D	Â

# **Reporting Owners**

<b>Reporting Owner Name / Address</b>	Relationships					
	Director	10% Owner	Officer	Other		
Tengler Mark C/O NEOS THERAPEUTICS, INC. 2940 N. HIGHWAY 360 GRAND PRAIRIE, TX 75050	Â	Â	Chief Technology Officer	Â		
Signatures						
/s/ Benjamin Piper, attorney-in-fact	07/22/2015					
**Signature of Reporting Person	Date					

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The Series C preferred stock is convertible into common stock on a 2.4-for-1 basis into the number of shares of common stock as shown
 (1) in column 3 at any time at the holder's election, and automatically upon the closing of the Issuer's initial public offering. The Series C preferred stock has no expiration date.

(2) This stock option is fully vested and exercisable.

## Â

### **Remarks:**

## Exhibit List: Exhibit 24.1 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.